{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:05:40Z","timestamp":1648699540006},"reference-count":25,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1536\/ihj.15-003","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T18:03:52Z","timestamp":1434564232000},"page":"462-465","source":"Crossref","is-referenced-by-count":3,"title":["Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization"],"prefix":"10.1536","volume":"56","author":[{"given":"Hironori","family":"Muraoka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Imamura T, Kinugawa K, Hatano M, <i>et al<\/i>. Low cardiac output stimulates vasopressin release in patients with stage d heart failure. Circ J 2014; 78: 2259-67.","DOI":"10.1253\/circj.CJ-14-0368"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kinugawa K. How to treat stage D heart failure? - When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-45. (Review)","DOI":"10.1253\/circj.CJ-11-0621"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Imamura T, Kinugawa K, Fujino T, <i>et al<\/i>. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-9.","DOI":"10.1253\/circj.CJ-14-0244"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Imamura T. Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease. Int Heart J 2014; 55: 482-3.","DOI":"10.1536\/ihj.14-217"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Imamura T, Kinugawa K, Minatsuki S, <i>et al<\/i>. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J 2014; 55: 131-7.","DOI":"10.1536\/ihj.13-221"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Imamura T, Kinugawa K, Minatsuki S, <i>et al<\/i>. Tolvaptan can improve clinical course in responders. Int Heart J 2013; 54: 377-81.","DOI":"10.1536\/ihj.54.377"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Packer M, Coats AJ, Fowler MB, <i>et al<\/i>. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.","DOI":"10.1056\/NEJM200105313442201"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865-9. (Review)","DOI":"10.1016\/j.amjcard.2007.11.023"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tardif JC, O\u2019Meara E, Komajda M, <i>et al<\/i>. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-15.","DOI":"10.1093\/eurheartj\/ehr311"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Epstein AE, DiMarco JP, Ellenbogen KA, <i>et al<\/i>. 2012 ACCF\/AHA\/HRS focused update incorporated into the ACCF\/AHA\/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013; 127: e283-352.","DOI":"10.1161\/CIR.0b013e318276ce9b"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. Curr Opin Cardiol 2006; 21: 20-6. (Review)","DOI":"10.1097\/01.hco.0000198983.93755.99"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Imamura T, Kinugawa K, Hatano M, <i>et al<\/i>. Preoperative beta-blocker treatment is a key for deciding left ventricular assist device implantation strategy as a bridge to recovery. J Artif Organs 2014; 17: 23-32.","DOI":"10.1007\/s10047-013-0748-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chandraprakasam S, Mentzer GG. Recent advances in the optimization of cardiac resynchronization therapy. Curr Heart Fail Rep 2015; 12: 48-60.","DOI":"10.1007\/s11897-014-0234-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hori M, Sasayama S, Kitabatake A, <i>et al<\/i>. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-30.","DOI":"10.1016\/j.ahj.2003.07.023"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cleland JG, Coletta AP, Freemantle N, Ahmed D, Rubis P, Clark AL. Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure. Eur J Heart Fail 2010; 12: 197-201.","DOI":"10.1093\/eurjhf\/hfp199"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hunt SA, Abraham WT, Chin MH, <i>et al<\/i>. 2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.","DOI":"10.1016\/j.jacc.2008.11.013"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dickstein K, Cohen-Solal A, Filippatos G, <i>et al<\/i>. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.","DOI":"10.1016\/j.ejheart.2008.08.005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kato N, Kinugawa K, Imamura T, <i>et al<\/i>. Trend of clinical outcome and surrogate markers during titration of beta-blocker in heart failure patients with reduced ejection fraction: relevance of achieved heart rate and beta-blocker dose. Circ J 2013; 77: 1001-8.","DOI":"10.1253\/circj.CJ-12-1241"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bristow MR, Gilbert EM, Abraham WT, <i>et al<\/i>. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94: 2807-16.","DOI":"10.1161\/01.CIR.94.11.2807"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mori Y, Nishikawa Y, Kobayashi F, Hiramatsu K. Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. Int Heart J 2013; 54: 15-22.","DOI":"10.1536\/ihj.54.15"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Swedberg K, Komajda M, B\u00f6hm M, <i>et al<\/i>. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Metra M, Nodari S, D\u2019Aloia A, Bontempi L, Boldi E, Cas LD. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 2000; 139: 511-21. (Review)","DOI":"10.1067\/mhj.2000.103544"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fox K, Ford I, Steg PG, <i>et al<\/i>. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-21.","DOI":"10.1016\/S0140-6736(08)61171-X"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T09:56:55Z","timestamp":1498211815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/56\/4\/56_15-003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.15-003","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}